Form 4: Teva CFO Sells Shares Under 10b5-1 Plan

Teva Pharmaceutical Industries Ltd. CFO Eliyahu Sharon Kalif sold a portion of his holdings in ordinary shares as part of a pre-arranged trading plan.

Summary

• Eliyahu Sharon Kalif, EVP and Chief Financial Officer of Teva Pharmaceutical Industries Ltd., reported a transaction involving the sale of ordinary shares.
• The sale occurred on June 11, 2026, and involved 106,563 ordinary shares.
• These shares were sold at a weighted average price of $34.0954, with individual transactions ranging from $33.985 to $34.25.
• The transaction was executed under a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.
• Following the transaction, Mr. Kalif beneficially owns 65,621 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sale can be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.

Negatives

• The CFO sold a significant number of shares (106,563), which could be perceived negatively by the market, although it was conducted under a pre-established plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership by an executive.

Industry Context

StockSavvy.ai notes that insider sales, even when conducted under a Rule 10b5-1 plan, can sometimes lead to investor scrutiny. However, these plans are designed to allow executives to diversify holdings or meet financial obligations without being perceived as trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal of reduced confidence by management, though the 10b5-1 plan provides a mitigating context.

Key Dates

Keywords

Teva Pharmaceutical Industries, Form 4, Insider Trading, Share Sale, Rule 10b5-1, CFO, Beneficial Ownership